Take Action: Support the MINI Act to Protect Patient Access to Genetic Therapies

Congress is considering the Maintaining Investments in New Innovation Act (MINI Act) [HR 1672], legislation to protect patient access to genetically targeted therapies (GTTs)—innovative treatments designed to address the underlying genetic causes of serious diseases.

Under current law, some of these therapies may face Medicare price controls earlier than similarly complex treatments, simply due to how they are classified. That shortened timeframe to recover research and development costs risks discouraging investment and limiting future treatment options.

Patients should not lose access to life-changing therapies because of a technical classification issue. The MINI Act would help correct this imbalance and preserve incentives for innovation.

Click Here to Tell Your Members of Congress to Support the MINI Act

Latest News

ASBM Urges CO PDAB to Reject Upper Payment Limits Without Patient Protections

On May 15, ASBM submitted comments to the Colorado Prescription Drug Affordability Board urging it not to impose an upper payment limit (UPL) on Cosentyx unless the Board can demonstrate that the policy will directly reduce patient out-of-pocket costs without disrupting access to treatment. ASBM emphasized that a UPL would reduce the amount paid by […]

ASBM Submits Comments to FDA on Biosimilar Draft Guidance

On May 11th, ASBM submitted comments on the FDA’s recently released draft guidance and Q&As aimed at “streamlining” biosimilar development by permitting the use of data from non-U.S.-licensed comparator products and foreign clinical studies in the U.S. biosimilar approval process. While efficiency is important, ASBM is concerned that these changes may lower evidentiary standards in […]

Tell Congress: Support the SAFE Drugs Act

ASBM is urging Congress to pass the SAFE Drugs Act of 2026, legislation designed to strengthen oversight of unsafe, unapproved, and mass-marketed copycat medicines. Pharmacy compounding plays an important and legitimate role in patient care when FDA-approved therapies are unavailable or when a patient has a specific clinical need that cannot be met by an […]